Affiris begins clinical testing of Alzheimer’s vaccine

Vienna, 19th July 2007. The Alzheimer's vaccine known as Affitope AD01 from Affiris has now entered the clinical phase of its development. All relevant regulatory and statutory approvals have been secured and this innovative treatment is now being tested on humans for the first time. This development means that the 8.5 million-Euro venture capital finance agreement the company concluded with Munich-based MIG-Fonds in April 2006 has reached a key milestone on schedule. Up to 24 Alzheimer's patients are to be vaccinated, with the aim of this initial phase I trial being to demonstrate the

vaccine's safety and its suitability for human use. The trial is being run at the Vienna General Hospital and is due to be completed within one year. If it can be successfully proven that the vaccine has a positive safety and suitability profile, the second stage of the clinical development process could begin as early as next year. The aim of this stage in clinical testing would be to demonstrate the vaccine's efficacy, a goal that no treatment anywhere in the world has yet achieved.

About AFFiRiS GmbH (as at May 2007): AFFiRiS GmbH develops peptide-based vaccines for the treatment of Alzheimer's disease, atherosclerosis and other serious diseases. The company has established platform technologies and registered the corresponding patent families. The first patents have already been issued. The company employs 30 highly qualified members of staff on 600 sqm of rented laboratory facilities at the Campus Vienna Biocenter. About MIG-Fonds: The participation of MIG Verwaltungs AG in Affiris GmbH represents the continuation of a tried-and-tested approach. Investment is only made in selected companies in Germany and Austria after their viability has been thoroughly audited. Their innovative, high-potential products and the entrepreneurial skills of their management teams are both key. MIG Verwaltungs AG is supported by Alfred Wieder AG. This specialist in venture capital is experienced in the sale of holdings and is therefore the first point of contact for any potential investors. Contact for Affiris GmbH: Dr. Walter Schmidt Campus Vienna Biocenter 2 A-1030 Vienna, Austria T +43 / 1 / 798 1575 10 Distribution: PR&D - Public Relations for Research & Development Campus Vienna Biocenter 2 A-1030 Vienna, Austria T +43 / 1 / 505 70 44 E contact@prd.at